KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Research & Development (2016 - 2025)

Sarepta Therapeutics (SRPT) has 15 years of Research & Development data on record, last reported at $517.2 million in Q4 2025.

  • For Q4 2025, Research & Development rose 1889.23% year-over-year to $517.2 million; the TTM value through Dec 2025 reached $583.6 million, up 29.15%, while the annual FY2025 figure was $583.6 million, 359.17% up from the prior year.
  • Research & Development reached $517.2 million in Q4 2025 per SRPT's latest filing, up from -$911.4 million in the prior quarter.
  • Across five years, Research & Development topped out at $583.6 million in Q1 2025 and bottomed at -$911.4 million in Q3 2025.
  • Average Research & Development over 5 years is $139.5 million, with a median of $205.6 million recorded in 2021.
  • The widest YoY moves for Research & Development: up 2589.4% in 2025, down 506.02% in 2025.
  • A 5-year view of Research & Development shows it stood at $197.3 million in 2021, then grew by 8.37% to $213.8 million in 2022, then plummeted by 368.92% to -$575.0 million in 2023, then skyrocketed by 104.52% to $26.0 million in 2024, then soared by 1889.23% to $517.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $517.2 million in Q4 2025, -$911.4 million in Q3 2025, and $394.2 million in Q2 2025.